from Yahoo Finance https://ift.tt/2Un2N9J

Warner Music Group shares jump in public debut. Yahoo Finance’s Jared Blikre shares the latest.

from Yahoo Finance https://ift.tt/2XuYwmv

The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data. We at Insider Monkey have plowed through 821 13F filings that hedge funds and well-known value investors are required to file by the SEC. The 13F […]

from Yahoo Finance https://ift.tt/2MnJ05q

In this article you are going to find out whether hedge funds think Apache Corporation (NYSE:APA) is a good investment right now. We like to check what the smart money thinks first before doing extensive research on a given stock. Although there have been several high profile failed hedge fund picks, the consensus picks among […]

from Yahoo Finance https://ift.tt/3eG5pXM

While dismissing most claims, U.S. District Judge Yvonne Gonzalez Rogers ruled late Tuesday that shareholders can sue over Chief Executive Tim Cook’s comments touting strong iPhone demand on a Nov. 1, 2018 analyst call, only a few days before Apple told its largest manufacturers to curb production. “Absent some natural disaster or other intervening reason, it is simply implausible that Cook would not have known that iPhone demand in China was falling mere days before cutting production lines,” Rogers wrote.

from Yahoo Finance https://ift.tt/3eMKYIJ

(Bloomberg) — Oil turned lower after U.S. government data showed fuel demand isn’t recovering as quickly as first believed.American gasoline supplies rose to the highest level in more than a month and distillate inventories jumped by the most since January 2019, according to the Energy Information Administation. Those increased offset a larger-than-expected decline in crude stockpiles, dragging West Texas Intermediate crude futures down by 1%.Production curbs by OPEC and its allies have helped the market move toward balance, after the massive demand destruction at the height of the virus pandemic in April. But the recovery remains tenuous, with U.S. producers signaling they’re already prepared to re-open wells and oil consumption still soft in most of the world. OPEC+’s commitment to its output-cut deal has also been thrown into question as concerns over cheating prompts Saudi Arabia to propose delaying the alliance’s June meeting.For more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2020 Bloomberg L.P.

from Yahoo Finance https://ift.tt/2yYol4L

When OPEC, Russia and their allies agreed in April to slash oil production, little did they expect that their initiative to prop up collapsing prices would be helped by a swift drop in U.S. output. Now that crude has rallied on the back of those cuts from below $20 a barrel to $40 or more, the group known as OPEC+ faces a fresh challenge: stopping U.S. shale production delivering another surprise by recovering equally quickly. “The plan is to stick to prices of $40-$50 per barrel because as soon as they rise any further to say $70 per barrel it encourages too much oil production, including U.S. shale,” said a Russian source familiar with OPEC+ talks on the issue.

from Yahoo Finance https://ift.tt/2Xu2iwv

President Donald Trump’s administration said on Wednesday it will bar Chinese passenger carriers from flying to the United States starting on June 16 as it pressures Beijing to allow U.S. air carriers to resume flights. The move, announced by the U.S. Department of Transportation, penalizes China after Beijing failed to comply with an existing agreement on flights between the world’s two largest economies. The order applies to Air China , China Eastern Airlines Corp, China Southern Airlines Co and Hainan Airlines Holding Co .

from Yahoo Finance https://ift.tt/2U7XcUp

(Bloomberg) — A formerly cautious analyst at SVB Leerink has changed his tune on the potential sales of Gilead Sciences Inc.’s Covid-19 treatment, remdesivir.Even bullish Wall Street analysts have been critical of Gilead’s chances of making a profit from the treatment, which received an emergency use designation from U.S. regulators in May. Public advocates have argued against drug and vaccine makers making any profit from the global pandemic but SVB Leerink analyst Geoffrey Porges is now forecasting that sales of remdesivir may reach $7.7 billion in 2022.Less than two months ago, Porges had said investors were giving a “generous amount of credit” for a drug that likely won’t be sold for a profit.The latest change is reason enough for Porges to raise his rating on Gilead shares to outperform from market perform, and increase his price target to $94, just $3 shy of the current Street high target. The new target, up from $85 previously, also includes more than $1 billion in sales from potential cancer medicines in a partnership with Arcus Biosciences Inc.“A valuation of $94+ is realistic, perhaps as soon as the company declares its price for commercial sale of remdesivir,” Porges wrote in a note to clients. He expects commercial sales of the drug to be priced at roughly $5,000 per course of treatment in the U.S., and $4,000 in Europe. Gilead, which has said it’s donating 1.5 million vials of the medicine globally, has probably already doled out that supply and will have to announce a price soon, according to the analyst.Clinicians are still awaiting more detailed results from the drug, which has shown a modest benefit in some studies. Meanwhile, biotechnology companies including Moderna Inc. are racing to develop a vaccine. Porges’s view, however, is that “SARS-nCoV2 is not going away, or being eliminated by vaccination.”Gilead shares rose as much as 1.5% in Wednesday trading. The stock has struggled since remdesivir received its authorization, and is down about 8% from May 1.(Updates shares in final paragraph)For more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2020 Bloomberg L.P.

from Yahoo Finance https://ift.tt/36UnvCM

At the end of February we announced the arrival of the first US recession since 2009 and we predicted that the market will decline by at least 20% in (Recession is Imminent: We Need A Travel Ban NOW). In these volatile markets we scrutinize hedge fund filings to get a reading on which direction each […]

from Yahoo Finance https://ift.tt/2U6tG1c